NovoCodex is based in Shaoxing Shi, Zhejiang Sheng, China. It has raised $123M in total funding. Latest round: Series C.
NovoCodex funding overview
NovoCodex is based in Shaoxing Shi, Zhejiang Sheng, China. NovoCodex has raised $123M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series C announced in March 2026. The round record for NovoCodex runs through 2026; nothing later has been disclosed. Investors on record include Dongguan Financial Holdings Group, CITIC Med Fund, Puhua Capital, Zhejiang Xinhai Asset Management, Minnesota Capital, Prosperity Investment and 3 others. 9 distinct backers are named across the disclosed rounds.
NovoCodex at a glance
Total raised
$123M
Latest round
Series C
Latest round date
March 2026
Headquarters
Shaoxing Shi, Zhejiang Sheng, China
Notable investors
Dongguan Financial Holdings Group, CITIC Med Fund, Puhua Capital, Zhejiang Xinhai Asset Management, Minnesota Capital, Prosperity Investment, Lilly Asia Ventures, MPCi
Frequently asked about NovoCodex funding
How much has NovoCodex raised?
NovoCodex has raised $123M in total disclosed funding across the rounds on record.
Who has invested in NovoCodex?
Dongguan Financial Holdings Group, CITIC Med Fund, Puhua Capital, Zhejiang Xinhai Asset Management, Minnesota Capital, Prosperity Investment are named among the investors backing NovoCodex.
What was the latest NovoCodex funding round?
The most recent disclosed round is a Series C, announced in March 2026.
Where is NovoCodex based?
NovoCodex is based in Shaoxing Shi, Zhejiang Sheng, China.
When did NovoCodex last raise?
The last disclosed NovoCodex round closed in March 2026 at Series C.
NovoCodex totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Shaoxing Shi below to benchmark round size and investor mix.
